Singapore · HSA Notification
Singapore's light-touch supplement regulation is changing. HSA revised its notification system in July 2026 and has proposed making it mandatory — here's exactly where things stand and what to do now.
Mandatory notification target
End of 2028
Full transition from Medicines Act to Health Products Act
Singapore has long been known for a "light-touch" approach to supplement regulation — no pre-market approval, a voluntary notification system, and reliance on strong post-market enforcement instead. That's changing. HSA revised its notification system in July 2026 and has separately proposed making notification mandatory, with full implementation targeted by the end of 2028. If Singapore is your first ASEAN market, understanding exactly where that transition stands right now matters more than it did a year ago.
The Health Sciences Authority (HSA) oversees health supplements under a category called Complementary Health Products (CHP) — which also covers traditional medicines and Chinese Proprietary Medicine. A health supplement, specifically, is a product that supplements the diet and supports or improves bodily health function, presented as capsules, tablets, softgels, powders, or liquids. It cannot be an injectable, cannot require sterile preparation, and cannot function as a meal or diet item — HSA is explicit that gummy-style "sweet, chewable outer shell with semi-solid or liquid core" formats fall outside the accepted dosage forms for this category, a distinction worth knowing before formulation decisions are locked in for the Singapore market.
Current model
Light-Touch
No pre-market approval required today
Enforcement
Post-Market
Sampling and adverse-reaction monitoring instead
Legal basis
Shifting
Medicines Act (1975) → Health Products Act
Term to know — CHP
Complementary Health Product — HSA's umbrella category covering health supplements, traditional medicines, and Chinese Proprietary Medicine. HSA provides a free self-help classification tool that lets a company confirm whether a specific product falls into this category, with a printable classification outcome for internal records.
Even without pre-market approval, one area is strictly enforced regardless of notification status: supplements must not be labelled, advertised, or promoted for medicinal purposes. There's no pre-market claim review to catch a problem before launch — HSA relies on active post-market monitoring, which means an overreaching claim can trigger enforcement well after a product is already selling, not before. This asymmetry is precisely why claims discipline matters more in Singapore than in markets with pre-market claim review — the absence of an early gatekeeper doesn't mean the absence of consequences, it just means those consequences arrive later and land on a product already generating revenue and customer trust that then has to be walked back.
From an optional database entry to a proposed legal requirement — four milestones so far.
Aug 2022
Voluntary notification database first introduced.
Jan 2026
Health Supplements Guidelines revised (GL-CHPB-3-001).
15 Jul 2026
VNS revised to a streamlined self-declaration model.
End of 2028
Mandatory notification targeted, under the Health Products Act.
Aug 2022
Voluntary notification database first introduced.
Jan 2026
Health Supplements Guidelines revised.
15 Jul 2026
VNS revised to a self-declaration model.
End of 2028
Mandatory notification targeted.
Common mistake
Assuming "voluntary" means "optional to ever bother with." Being on HSA's notification list is a visible market signal to retailers and distributors today — and starting the practice now means your compliance file is already built when notification becomes mandatory, rather than being assembled under deadline pressure.
Brand owner, manufacturer, and importer name & address
Product name and dosage form
Contact details for the notifying party
Self-assessment against HSA's safety and labelling standards
CoA and GMP documentation held on file (not submitted upfront)
CHP classification confirmed via HSA's self-help tool
Notably, the supporting technical dossier — CoA, GMP certificates, manufacturer documentation — doesn't need to be submitted to HSA at the point of notification itself. It needs to exist, be current, and be organised well enough to produce quickly if HSA requests it. That distinction matters: notification is a declaration backed by evidence you hold, not a review process HSA conducts on your behalf. Brands that treat notification as a paperwork formality, without the underlying documentation genuinely in order, are the ones most exposed once the framework shifts from voluntary to mandatory and that documentation starts getting checked in earnest.
How Biox Nexevo Handles This
Compliance-ready before it's mandatory, not after.
Every product we manufacture ships with a complete CoA, GMP certification, and manufacturer documentation on file from day one — so voluntary HSA notification today, and mandatory notification from 2028, both start from a compliance foundation that already exists.
Not yet. As of 2026, notification remains voluntary under HSA's revised self-declaration model, introduced 15 July 2026. HSA has proposed making notification mandatory under the Health Products Act, with full implementation targeted by the end of 2028.
CHP is HSA's category covering health supplements, traditional medicines, and Chinese Proprietary Medicine. HSA provides a self-help classification tool to confirm whether a specific product falls into this category.
No. HSA is explicit that notification does not constitute product approval or endorsement. Its purpose is traceability — so that in the event of a recall, authorities can quickly identify the manufacturer, importer, and product details.
Appearing on HSA's publicly accessible notification list is a market signal to retailers, distributors, and consumers that a brand takes regulatory obligations seriously — a meaningful differentiator while consumer confidence in supplement oversight is still developing, and useful preparation for when notification becomes mandatory.
Supplements must not be labelled, advertised, or promoted for medicinal purposes. This is one of the most strictly enforced areas of Singapore's supplement regulation, backed by active post-market monitoring rather than pre-market claim review.
Want to get ahead of Singapore's 2028 shift?
Talk to Us on WhatsAppSources: Health Sciences Authority (HSA), Singapore — hsa.gov.sg; HSA Health Supplements Guidelines GL-CHPB-3-001 (January 2026); HSA public consultation on Complementary Health Products regulatory framework (2026). This page reflects the regulatory position as of September 2026 — confirm current requirements directly with HSA, as the mandatory notification framework is still being finalised.
Continue Your Research